Skip to main content

Table 2 Adverse events

From: A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas

Group

Toxicity

Grade 3

Grade 4

Total

Dose level

Hematologic

Thrombocytopenia

3

3

6

4

Neutropenia

5

5

4

Lymphocyte count decreased

1

1

4

White blood cell decreased

1

1

4

Gastrointestinal

Lipase increased

3

3

4

ALT increased

3

3

4

Vomiting

3

3

4, 5

Serum Amylase increased

2

2

4

Abdominal pain

1

1

5

Anorexia

1

1

5

AST increased

1

1

4

Stomatitis

1

1

4

Weight loss

1

1

4

Metabolic

Hypophosphatemia

6

6

4, 5

Hypokalemia

2

2

4, 5

Hypocalcemia

1

1

4

Hyponatremia

1

1

4

Other

Bone infection

1

1

4

  1. Only adverse events (AEs) of Grade ≥ 3 and with attribution of “Possible” or above reported. ALT alanine aminotransferase, AST aspartate aminotransferase, ANC absolute neutrophil count